Standard BioTools Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Michael Egholm
- Full Time Employees
- 389
- Sector
- Healthcare
- Industry
- Medical - Equipment & Services
- Address
- 50 Milk Street Boston MA United States of America 02109
- IPO Date
- Feb 10, 2011
- CIK
- 0001162194
- Website
- standardbio.com
- Similar Companies
- Business
- Standard BioTools Inc., alongside its affiliated entities, delivers a diverse array of scientific instruments, consumables, and specialized services to researchers globally, facilitating the advancement of therapeutic development across the Americas, Europe, the Middle East, Africa, and Asia-Pacific regions. The company operates through two main business areas: Proteomics and Genomics. These segments encompass advanced instrumentation, necessary consumables, software solutions, and comprehensive services, all built upon proprietary technologies for identifying proteins, genes, and understanding their functions. In proteomics, Standard BioTools offers the CyTOF® technology platform, which employs metal-tagged antibodies and time-of-flight mass spectrometry to achieve high-multiplexing capabilities and eliminate signal interference, providing deep insights into cellular processes and disease mechanisms. Key systems include the CyTOF XT PRO and the Hyperion XTi Imaging System, designed for comprehensive single-cell and spatial protein analysis. The company's offerings also recently included the SomaScan platform for broad protein measurement, though it was strategically sold to Illumina in June 2025, with the transaction anticipated to finalize in the first half of 2026, aiming to streamline operations and enhance financial flexibility. For genomics, Standard BioTools provides microfluidics-based systems like the Biomark™ X9 System, which reimagines high-throughput genomic applications for quantitative polymerase chain reaction (qPCR) and next-generation sequencing (NGS) library preparation. These innovative tools are supplied for research use only to a broad clientele, including academic institutions, translational and clinical research centers, cancer research facilities, biopharmaceutical and biotechnology firms, as well as those in plant and animal research. Standard BioTools, which was formerly known as Fluidigm Corporation, rebranded in April 2022 and was initially established in 1999, maintaining its headquarters in South San Francisco, California. The company is currently undergoing a restructuring, including a reduction in its global workforce and consolidation of R&D, to improve operational efficiency and accelerate its path to profitability.
Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026
Are DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders?
Are DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders?
Standard BioTools Announces Filing of Registration Statement in Connection with Treeline Biosciences Transaction
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AstroNova, Inc. (Nasdaq – ALOT), Open Lending Corporation (Nasdaq – LPRO), Huntsman Corporation (NYSE – HUN), Standard BioTools Inc. (Nasdaq – LAB)
LiveRamp Launches Agentic Partner Program to Fast-Track Agentic Deployments for Customers
Are ROKU, PAYO, LAB, FOX Obtaining Fair Deals for their Shareholders?
LAB Stock Alert: Halper Sadeh LLC is Investigating Whether Standard BioTools Inc. is Obtaining a Fair Price for its Shareholders
LAB Stock Alert: Halper Sadeh LLC is Investigating Whether Standard BioTools Inc. is Obtaining a Fair Price for its Shareholders
Labrador Gold to Host Investor Webinar on the Mariposa Gold Project in Yukon's White Gold District
Labrador Gold Announces 2026 Exploration Plans for Pacific Ridge's White Gold Projects
Standard BioTools Inc. (LAB) Discusses Merger and Strategic Rationale Prepared Remarks Transcript
Standard BioTools and Treeline Biosciences Announce Merger Agreement
Standard BioTools (LAB) Reports Q1 Loss, Tops Revenue Estimates
Standard BioTools Reports First Quarter 2026 Financial Results
Reviewing Standard BioTools (NASDAQ:LAB) & Zhongchao (NASDAQ:ZCMD)
Standard BioTools to Announce First Quarter 2026 Financial Results on May 5, 2026
PPJ Enterprise (OTCMKTS:PPJE) and Standard BioTools (NASDAQ:LAB) Financial Comparison
Standard BioTools Reports Fourth Quarter and Full Year 2025 Financial Results
Standard BioTools (LAB) Expected to Announce Quarterly Earnings on Tuesday